Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Employee Stock Purchase Programs (Detail)

v3.7.0.1
Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 4,807 $ 3,023 $ 7,736 $ 5,889
Fortress Companies [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense [1] 3,094 1,051 4,180 2,330
Employee Awards [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 1,690 1,969 3,520 3,553
Non-Employee Awards [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 23 $ 3 $ 36 $ 6
[1] Consists of approximately $19,000 of Avenue's compensation expenses, approximately $2.4 million of Checkpoint's compensation expense, approximately $73,000 of JMC's compensation expenses, approximately $34,000 of Helocyte's compensation expenses, approximately $6,000 of Cellvation's compensation expenses and approximately $183,000 of of NHLD's compensation expenses on stock and option grants for the three months ended June 30, 2017 and consists of approximately $24,000 of Avenue's compensation expenses, approximately $3.4 million of Checkpoint's compensation expense, approximately $119,000 of JMC's compensation expenses, approximately $81,000 of Helocyte's compensation expenses, approximately $14,000 of Cellvation's compensation expenses and approximately $183,000 of of NHLD's compensation expenses on stock and option grants for the six months ended June 30, 2017. Consists of approximately $9,000 of Avenue's compensation expenses, approximately $0.8 million of Checkpoint's compensation expense, approximately $147,000 of JMC's compensation expenses and approximately $93,000 of Helocyte's compensation expenses on stock grants for the three months ended June 30, 2016, and approximately $18,000 of Avenue's compensation expenses, approximately $1.9 million of Checkpoint's compensation expense, approximately $328,000 of JMC's compensation expenses and approximately $93,000 of Helocyte's compensation expenses on stock grants for the six months ended June 30, 2016.